Following the success of Ozempic®, Wegovy®, and other GLP-1 receptor agonists, pharmaceutical companies are racing to develop the next wave of metabolic drugs. These new therapies build on the proven benefits of currently approved GLP-1s—lowering blood sugar, supporting weight loss, and reducing cardiovascular risk—while aiming for even greater results in weight management and metabolic health.
Curious about the science behind today’s most talked-about diabetes and weight-management treatments? Our new, four-part blog series on GLP-1 Agonists will break down everything you need to know — from how these drugs work, to their real-world results, side effects, and what’s coming next in the pipeline. Today, we’re covering how someone might choose between GLP-1
Curious about the science behind today’s most talked-about diabetes and weight-management treatments? Our new, four-part blog series on GLP-1 Agonists will break down everything you need to know — from how these drugs work, to their real-world results, side effects, and what’s coming next in the pipeline. GLP-1 stands for glucagon-like peptide-1. It’s an incretin
The mRNA technology behind the COVID-19 vaccines that saved millions of lives during the pandemic may also help fight cancer, according to new research published in Nature. Scientists found that the Pfizer and Moderna mRNA vaccines can strengthen the immune system’s ability to recognize and kill tumor cells, even when the vaccines were originally designed
Eli Lilly is moving closer to bringing its experimental weight loss pill, orforglipron, to market after releasing positive results from its latest phase 3 clinical trial. The study, called Attain-2, tested the once-daily pill in people who are overweight or obese and also have Type 2 diabetes—a group often harder to treat. The trial found
Novo Nordisk’s popular weight-loss drug Wegovy has just received a new approval from the U.S. Food and Drug Administration (FDA)—this time for treating a serious liver condition called metabolic dysfunction-associated steatohepatitis (MASH). This marks Wegovy’s third approved use, following its approvals for obesity and reducing cardiovascular risk. MASH, once known as NASH, is caused by
The availability of COVID-19 vaccines for young children in the U.S. could shrink this fall as the Food and Drug Administration (FDA) considers ending the emergency use authorization (EUA) for Pfizer-BioNTech’s vaccine in kids ages 6 months to 4 years. Pfizer says it is in discussions with the FDA and has asked to keep the
The FDA has approved a safer dosing schedule for Eli Lilly’s Alzheimer’s drug, Kisunla, which could make it more appealing to doctors and patients. The updated schedule reduces the risk of a serious side effect called ARIA-E—brain swelling caused by anti-amyloid drugs. Originally, Kisunla was given in higher doses early on. Now, the drug will
De plus en plus d’Américains se tournent vers des médicaments contre le diabète comme Ozempic, non pas pour traiter le diabète, mais pour perdre du poids. Une nouvelle étude révèle que l’utilisation des médicaments GLP-1 par des adultes américains sans diabète a plus que triplé entre 2018 et 2022. Durant cette période, les dépenses annuelles
AstraZeneca prend de l’avance avec son inhalateur Breztri Aerosphere, visant à élargir son utilisation au-delà de la maladie pulmonaire obstructive chronique (MPOC) pour traiter également l’asthme. Cette démarche pourrait rapprocher l’entreprise de son objectif de ventes annuelles de 3 à 5 milliards de dollars. Breztri est un inhalateur « 3-en-1 » qui combine trois médicaments pour faciliter
